National medicines policies - a review of the evolution and development processes

被引:16
作者
Hoebert J.M. [1 ]
van Dijk L. [2 ]
Mantel-Teeuwisse A.K. [1 ]
Leufkens H.G.M. [1 ]
Laing R.O. [3 ]
机构
[1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht
[2] Netherlands Institute for Health Services Research (NIVEL), Utrecht
[3] Department of Essential Medicines and Health Products, World Health Organization, Geneva
关键词
Development; Medicines; National medicines policy; Opportunities; Policy process;
D O I
10.1186/2052-3211-6-5
中图分类号
学科分类号
摘要
Objectives: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and provides a comprehensive framework to develop all components of a national pharmaceutical sector. To meet the health needs of the population, there is a general need for medicine policies based on universal principles, but nevertheless adapted to the national situation. This review aims to provide a quantitative and qualitative (describing the historical development) study of the development process and evolution of NMPs.Methods: The number of NMPs and their current status has been obtained from the results of the assessment of WHO Level I indicators. The policy formulation process is examined in more detail with case studies from four countries: Sri Lanka, Australia, former Yugoslav Republic of Macedonia and South Africa.Results: The number of NMPs worldwide has increased in the last 25 years with the highest proportional increase in the last 5-10 years in high-income countries. Higher income countries seem to have more NMP implementation plans available and have updated their NMP more recently. The four case studies show that the development of a NMP is a complex process that is country specific. In addition, it demonstrates that an appropriate political window is needed for the policy to be passed (for South Africa and the FYR Macedonia, a major political event acted as a trigger for initiating the policy development). Policy-making does not stop with the official adoption of a policy but should create mechanisms for implementation and monitoring. The NMPs of the FYR Macedonia and Australia provide indicators for monitoring.Conclusions: To date, not all countries have a NMP since political pressure by national experts or non-governmental organizations is generally needed to establish a NMP. Case studies in four countries showed that the policy process is just as important as the policy document since the process must create a mechanism by which all stakeholders are brought together and a sense of collective ownership of the final policy may be achieved. © 2013 Hoebert et al.
引用
收藏
相关论文
共 44 条
[1]  
Kanji N., Hardon A., Harnmeijer J.W., Mamdani M., Walt G., Drugs Policy in Developing Countries, (1992)
[2]  
Another Development in Pharmaceuticals. Development Dialogue, Volume 2, (1985)
[3]  
Frisher M., Martino O., Crome I., Croft P., Trends in drug misuse recorded in primary care in the UK from 1998 to 2005, J Public Health (Oxf), 31, 1, pp. 69-73, (2009)
[4]  
Equitable access to essential medicines: a framework for collective action, (2004)
[5]  
Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing R., Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis, Lancet, 373, 9659, pp. 240-249, (2009)
[6]  
Dukes MNG H.R.F.M., de Joncheere C.P., Rietveld A.H., Prices, affordability and cost containment, (2003)
[7]  
't Hoen E.F.M., The Global Politics of Pharmaceutical Monopoly Power, (2009)
[8]  
Delivering on the Global Partnership for Achieving the Millennium Development Goals, in MDG Gap Task Force Report, (2008)
[9]  
Calabrese L.H., Changing patterns of morbidity and mortality in HIV disease, Cleveland Clinical Journal of Medicine, 68, 2, pp. 109-110, (2001)
[10]  
How to develop and implement a national drug policy, in WHO Policy Perspectives on Medicines, (2003)